The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy

[1] Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29

[2] Ma J(2007)Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2106-2131

[3] Zou Z(1994)Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152 1843-1849

[4] Jemal A(1997)Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control Urol Clin North Am 24 395-406

[5] Thompson I(2005)Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 433-439

[6] Thrasher JB(2008)Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 6302-6309

[7] Aus G(2011)Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges Clin Chem 57 1242-1255

[8] Burnett AL(2009)Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann Oncol 20 27-33

[9] Canby-Hagino ED(2007)Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 7053-7058

[10] Cookson MS(2012)Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemical failure after radical prostatecto Int J Mol Med 30 896-904

[1] Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29

[2] Ma J(2007)Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2106-2131

[3] Zou Z(1994)Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152 1843-1849

[4] Jemal A(1997)Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control Urol Clin North Am 24 395-406

[5] Thompson I(2005)Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 433-439

[6] Thrasher JB(2008)Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 6302-6309

[7] Aus G(2011)Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges Clin Chem 57 1242-1255

[8] Burnett AL(2009)Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann Oncol 20 27-33

[9] Canby-Hagino ED(2007)Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 7053-7058

[10] Cookson MS(2012)Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemical failure after radical prostatecto Int J Mol Med 30 896-904